Horizon Pharma plc (HZNP) Receives ‘Analyst’ Rating

Horizon Pharma plc (HZNP) : Zacks Investment Research ranks Horizon Pharma plc (HZNP) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.29, which indicates as a Strong Buy.

Horizon Pharma plc (HZNP) : Currently there are 7 street experts covering Horizon Pharma plc (HZNP) stock. The most bullish and bearish price target for the stock is $45 and $24 respectively for the short term. The average price target of all the analysts comes to $32.29. The estimated standard deviation from the target is $8.46.


Also, Major Brokerage house, Citigroup maintains its ratings on Horizon Pharma plc (NASDAQ:HZNP). In the latest research report, Citigroup raises the target price from $18 per share to $21 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on August 9, 2016.

Horizon Pharma plc (NASDAQ:HZNP): The stock opened in the green at $19.65 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $19.905 and a low of $19.27 for the day. The stock did not find buyers even at the lows and closed at $19.58 recording a loss of -0.25%. 2,896,202 shares exchanged hands during the trading day. The stock had closed at $19.63 in the previous days trading.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.